Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

Nonaka, Kenji; Kakikawa, Taro; Sato, Asako; Okuyama, Kotoba; Fujimoto, Go; Kato, Naoki; Suzuki, Hideyo; Hirayama, Yukio; Ahmed, Tuli; Davies, Michael J.; Stein, Peter

doi:10.1016/j.diabres.2007.08.021

Cited by 193 publications

(179 citation statements)

References 21 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…Most trials were designed as short term studies (12 to 24 weeks) with similar characteristics, including diet and exercise counseling for patients and wash-out periods of oral anti-diabetic therapy and dose stabilization periods ranging from 6 to 19 weeks. In the monotherapy trials, sitagliptin therapy compared to placebo resulted in statistically significant improvements in A1C and fasting glucose (52,(60)(61)(62). Similar reductions from baseline in 2-hour PPG values were observed in these trials (-41.4mg/dL to -48.6 mg/dL) (61,62).…”

Section: Sitagliptinsupporting

confidence: 52%

“…Sitagliptin therapy has been shown to be weight neutral in all clinical trials except in one study in which sitagliptin given with metformin resulted in weight reduction of 1.5kg after 52 weeks of treatment (63). In the clinical trials summarized in Table 4, gastrointestinal adverse events occurred in 12% to 21% of patients and were generally mild-to-moderate in severity (53,54,(60)(61)(62)(63). Other adverse events reported in patients (>3%) taking sitagliptin included upper respiratory tract infection, nasopharyngitis and headache (53,54,(61)(62)(63).…”

Section: Sitagliptinmentioning

confidence: 99%

See 1 more Smart Citation

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes

Davidson

Parente²,

Gross

2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

the prevalence of diabetes and impaired glucose tolerance is predicted to dramatically increase over the next two decades. clinical therapies for type 2 diabetes mellitus (t2dM) have traditionally included lifestyle modification, oral anti-diabetic agents, and ultimately insulin initiation. In this report, we review the clinical trial results of two innovative t2dM treatment therapies that are based on the glucoregulatory effects of incretin hormones. Incretin mimetics are peptide drugs that mimic several of the actions of glucagon-like peptide-1 (gLP-1) and have been shown to lower glycated hemoglobin (A1c) levels in patients with t2dM. Additionally, incretin mimetics lower postprandial and fasting glucose, suppress elevated glucagon release, and are associated with progressive weight reduction. dipeptidyl peptidase-4 (dPP-4) inhibitors increase endogenous gLP-1 levels by inhibiting the enzymatic degradation of gLP-1. clinical studies in patients with t2dM have shown that dPP-4 inhibitors reduce elevated A1c, lower postprandial and fasting glucose, suppress glucagon release, and are weight neutral. collectively, these new drugs, given in combination with other antidiabetic agents, such as metformin, sulfonylureas, and/or thiazolidinediones, can help restore glucose homeostasis in poorly controlled patients with t2dM. É previsto que a prevalência de diabetes e a intolerância à glicose aumente dramaticamente ao longo das próximas duas décadas. As terapias clínicas para diabetes melito tipo 2 (dM2) têm tradicionalmente incluído modificação do estilo de vida, agentes antidiabéticos orais e, por último, o início da insulina. neste artigo, revisamos os resultados dos estudos clínicos de duas terapias inovadoras no tratamento do dM2 baseadas nos efeitos glicorregulatórios dos hormônios incretina. Os incretinomiméticos são medicamentos peptídeos que mimetizam várias das ações do peptídeo semelhante ao glucagon-1 (gLP-1) e têm demonstrado reduzir níveis de hemoglobina glicada (A1c) em pacientes com dM2. Adicionalmente, incretinomiméticos reduzem as glicemias pós-prandial e de jejum, suprimem a liberação elevada do glucagon, e são associados com redução de peso. Os inibidores da dipeptidil peptidase-4 (dPP-4) aumentam os níveis de gLP-1 endógeno pela inibição da degradação enzimática do gLP-1. Estudos clínicos em pacientes com dM2 têm demonstrado que inibidores da dPP-4 reduzem A1c elevada, reduzem as glicemias pós-prandial e de jejum, suprimem a liberação elevada do glucagon e são neutros quanto ao peso. coletivamente, estas novas medicações, administradas em combinação com outros agentes antidiabéticos, como metformina, sulfoniluréias e/ou tiazolidinedionas (tZds), podem ajudar a recuperar a homeostase glicêmica de pacientes com dM2 não-controlados. (Arq Bras Endocrinol Metab

show abstract

Section: Sitagliptinsupporting

confidence: 52%

Section: Sitagliptinmentioning

confidence: 99%

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes

Davidson

Parente²,

Gross

2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…In a recently published study, treatment with sitagliptin 100 mg q.d. for 12 weeks improved fasting and postprandial glycemic control and was generally well tolerated in Japanese patients with type 2 diabetes mellitus 7 . In October 2010, sitagliptin became the first DPP‐4 inhibitor available in Japan.…”

Section: Introductionmentioning

confidence: 99%

Obesity may attenuate the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients

Bando¹,

Kanehara

Aoki

et al. 2011

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction: The aim of the present study was to assess the independent predictors of the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients.Materials and Methods: Data were retrieved from the medical records of 151 type 2 diabetic patients who had been taking sitagliptin 25 or 50 mg once daily for inadequate glycemic control for at least 12 weeks, with or without other oral hypoglycemic agents. Spearman’s rank correlation coefficients were calculated to investigate correlations between two independent continuous variables. Multiple stepwise regression analysis was used to identify independent predictors of reductions in HbA1c levels after 12 weeks of sitagliptin treatment (ΔHbA1c).Results: In all patients combined, Spearman’s rank correlation coefficients showed that ΔHbA1c was significantly correlated with baseline HbA1c alone (r = 0.371, P < 0.0001). However, multiple linear regression analysis among all patients using baseline variables revealed that the independent factors contributing to ΔHbA1c, in order of importance, were method of prescribing (P < 0.0001), baseline HbA1c (P < 0.0001), body mass index (BMI; P = 0.004), and duration of diabetes (P = 0.024).Conclusions: Our analysis may provide novel evidence that increased BMI contributes, in part, to attenuation of the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients. Analysis of a larger population over a longer period of time is warranted to confirm these findings. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2011.00156.x, 2011)

show abstract

“…Considering their relevant mechanisms and underlying pathophysiology, DPP-4 inhibitors may be more suitable for the treatment of non-obese subjects with diabetes, specifically in regard to the potentiation of insulin secretion and β-cell mass preservation (6)(7)(8). Some clinical studies in which DPP-4 inhibitors were examined in Asian diabetics with relatively low body mass index (BMI) have already demonstrated their greater efficacy in lowering levels of HbA1c (9,10). Another drug proposed for the preservation of β-cells is thiazolidinedione (TZD), which is generally believed to reduce glucolipotoxicity by improving insulin sensitivity (11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Both sitagliptin analogue & pioglitazone preserve the β-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice

Yeom

Kim²,

Park³

et al. 2011

BMB Reports

View full text Add to dashboard Cite

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

Cited by 193 publications

References 21 publications

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes

Obesity may attenuate the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients

Both sitagliptin analogue & pioglitazone preserve the β-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice

Contact Info

Product

Resources

About